Healthcare (May 2021)

Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas

  • Antonello Sica,
  • Beniamino Casale,
  • Caterina Sagnelli,
  • Maria Teresa Di Dato,
  • Marco Rispoli,
  • Mario Santagata,
  • Pietro Buonavolontà,
  • Alfonso Fiorelli,
  • Paola Vitiello,
  • Stefano Caccavale,
  • Massimiliano Creta,
  • Anna Maria Salzano,
  • Evangelista Sagnelli,
  • Elisabetta Saracco,
  • Giuseppe Gazzerro,
  • Vincenzo Famiglietti,
  • Dario Tammaro,
  • Alfonso Papa

DOI
https://doi.org/10.3390/healthcare9050589
Journal volume & issue
Vol. 9, no. 5
p. 589

Abstract

Read online

Chest pain following a trans-thoracic biopsy often has multiple etiologies, especially in patients with lymphomas. Pathological neuronal mechanisms integrate with an overproduction of IL-6, TNF-α, IL1-β by macrophages and monocytes, which amplifies inflammation and pain. In consideration of this complex pathogenesis, international guidelines recommend diversified analgesia protocols: thoracic epidural, paravertebral block, and systemic administration of opioids. This study reports an attempt to reduce chest pain and prevent chronic pain in 51 patients undergoing trans-thoracic biopsy for mediastinal lymphoma. The entity of pain, measured 72nd hour after biopsy by the Numerical Rating Scale (NRS), was compared with that seen at a 6th month checkpoint in 46 patients. The pain decreased in all cases. At the 6th month checkpoint, among 31 opioid-treated patients, none of the 16 patients with NRS p < 0.01). Of 10 patients undergoing thoracotomy and treated with opioids, eight had a NRS of no more than 2, of which six had no chronic pain. Of the twenty-one patients who underwent VATS biopsy and were treated with opioids, fifteen had NRS no greater than 2, of which ten had no chronic pain. Subgroups of patients biopsied under mediastinotomy or video-assisted thoracoscopic surgery (VATS) and treated with thoracic epidural analgesia (TEA) or PVB were too small for such analysis.

Keywords